Thyroid Gland Papillary Carcinoma

When evaluating a subcarinal mediastinal mass following thyroid cancer surgery, it is important to include vascular lesions, such as BAAs, in the differential diagnosis, although these are rare. This case demonstrates that minimally invasive thoracoscopic resection provides both diagnostic confirmation and therapeutic benefits when preoperative diagnosis remains uncertain.

This study provides exploratory genetic and clinical evidence supporting a causal, protective role for specific peripheral and tumor-infiltrating B-cell subsets in PTC. Naïve B cells and CD27+ unswitched memory B cells are linked to indolent tumor behavior and favorable prognosis, highlighting their potential as biomarkers for risk stratification and non-invasive monitoring in PTC management.

In addition, peripheral immune alterations and immune-related gene activation suggest potential synergy between MWA and immune checkpoint blockade. Collectively, MWA not only provides effective local tumor destruction but also reshapes the tumor immune microenvironment, offering a rationale for combined thermal and immunotherapeutic strategies in thyroid oncology.

P=N/A, N=9, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

P=N/A, N=15, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

We also observed a single case of bilateral pheochromocytoma in which loss of Sdhc was not the driver. While our findings did not recapitulate features of the Hensen Model, this study does suggest that chromosomal structure, even in the form of a seemingly innocuous single Robertsonian configuration, can dramatically impact clinical phenotype.

The proteins were differentially expressed in patients with Hashimoto's thyroiditis with papillary thyroid carcinoma compared to those with benign nodules. COL12A1, as a key molecule with potential differential diagnostic value, provides a promising target for future research and validation.

Neoadjuvant therapy shows promise in improving resectability for unresectable and poorly differentiated thyroid cancers, with 51% of patients achieving R0 resection. Future studies should investigate optimal therapy selection, timing, dosing, and long-term outcomes, including disease-specific survival and patient-reported measures.

HRas proto-oncogene (HRAS) and STAG2 cohesin complex component (STAG2) were synchronously identified as the driver genes, while the OTUB2 deletion mutation may contribute to tumor proliferation and disease progression in TCTs.

This research sets the stage to further investigate the molecular mechanisms underlying the novel nonsense mutation. Additionally, it incites other research to explore the frequency of this mutation in other populations and finally to conduct functional studies.

These results may be important in terms of obtaining new immunohistochemical clues for diagnosis and carcinogenesis in thyroid PTCs and their metastases. The number of cases in our study is limited, and we think that supporting the results with a large series of studies may contribute to the diagnosis and prognosis of the patients.

The BRAFV600E mutation and larger tumor size are linked to increased maximum, mean, and peak FDG uptake values on [18F]FDG-PET/CT in patients with recurrent PTC. These findings improve understanding of mutation-associated metabolic behavior in recurrent PTC; however, they do not support changes in clinical management or risk stratification based solely on FDG PET/CT metrics or BRAFV600E status. Further research should investigate the potential of [18F]FDG-PET/CT metrics as biomarkers for guiding individualized treatment strategies in BRAFV600E-positive PTC.